Homechevron_rightAll Peptideschevron_rightRetatrutide Injection Pen

verified_user

Safety data sheet

Standardized safety protocols and material specifications for professional use.

analytics

Certificate of Analysis

Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-retatrutide-injection-pen-10mg

Official Product Data Sheet

Retatrutide Injection Pen (10mg)

High >98% Purity

Vial Contents

10 mg Retatrutide (3 mL pre-filled injection pen)

Includes

Ready-to-use multi-dose injection pen — no mixing required

Form

Pre-filled multi-dose pen

Purity

≥98%, third-party verified

Sequence

Triple Agonist (GLP-1/GIP/Glucagon)

Molecular Formula

See chemical properties

Molecular Mass

≈4731 g/mol

CAS No.

2381089-83-2

Solubility

Concentration: ≈3.33 mg/mL | Per click: 1 unit ≈ 33.3 mcg

Storage

Refrigerate at 2–8 °C. Protect from light. Do not freeze.

Authorized Resellers

Available through our trusted partners

verifiedVerified

123peptide.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new

verifiedVerified

Depeptidenwinkel.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new

View all authorized resellersshopping_cart

swipe_rightSwipe to see all tabs

Scientific Background

Retatrutide is an advanced triple-agonist compound that simultaneously activates GLP-1, GIP, and glucagon receptors for comprehensive influence on appetite, energy expenditure, and fat metabolism. Phase 3 TRIUMPH trial data show up to 28.7% body weight reduction — among the highest seen in any weight-loss compound to date.

Intended Research Use

Triple GLP-1/GIP/glucagon receptor activation research
Appetite suppression and energy expenditure studies
Visceral and stubborn fat targeting
Metabolic syndrome and obesity research
Comparative efficacy vs. dual and single-agonist compounds

menu_bookScientific Publications

article

N Engl J Med (2023)

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/37366315/

article

Lancet (2023)

Retatrutide for Type 2 Diabetes

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/37364343/

article

Nat Med (2024)

Retatrutide for Metabolic Liver Disease

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/38877164/

warning

FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.

Possible stacks with other peptides

Synergistic combinations for enhanced research outcomes

Retatrutide's triple-agonist action pairs well with complementary metabolic and recovery peptides.

GLOW Blend 70mg (70mg vial)

arrow_forward

myo-glow-blend-70mg

Reduce side-effects and add regenerative benefits — GLOW's BPC-157/TB-500/GHK-Cu blend provides tissue repair and skin quality alongside Retatrutide's metabolic action.